In addition, we demonstrated that BLCA (P < 0.001), KIRC (P = 0.01), KIRP (P = 0.001), prostate adenocarcinoma (PRAD) (P = 0.034), and SKCM (P = 0.004) patients with higher expression of PCSK9 have a shorter DSS (Fig. 2B, Table S3). Here, PCSK9 is linked to prostate adenocarcinoma.